| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Welgene Biotech Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$22.80 |
| 52 Week High | NT$28.00 |
| 52 Week Low | NT$22.00 |
| Beta | 0.36 |
| 1 Month Change | 1.33% |
| 3 Month Change | 0.44% |
| 1 Year Change | 1.33% |
| 3 Year Change | -18.28% |
| 5 Year Change | 3.64% |
| Change since IPO | -17.92% |
Recent News & Updates
Recent updates
Is Welgene Biotech Co.,Ltd.'s (GTSM:6661) 4.7% Dividend Sustainable?
Mar 19
Are Welgene BiotechLtd's (GTSM:6661) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 10
Welgene Biotech Co.,Ltd.'s (GTSM:6661) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 13Know This Before Buying Welgene Biotech Co.,Ltd. (GTSM:6661) For Its Dividend
Dec 10Shareholder Returns
| 6661 | TW Life Sciences | TW Market | |
|---|---|---|---|
| 7D | 1.8% | -6.7% | -5.7% |
| 1Y | 1.3% | -29.5% | 23.8% |
Return vs Industry: 6661 exceeded the TW Life Sciences industry which returned -29.5% over the past year.
Return vs Market: 6661 underperformed the TW Market which returned 23.8% over the past year.
Price Volatility
| 6661 volatility | |
|---|---|
| 6661 Average Weekly Movement | 4.4% |
| Life Sciences Industry Average Movement | 5.5% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.5% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6661 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6661's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | n/a | www.welgene.com.tw |
Welgene Biotech Co.,Ltd. provides genetic testing services. The company offers research services, including sequencing, microarray, qPCR verification, nucleic acid extraction/QC, LCM single cell experiment, and bioinformatics analysis services; and Cytoscan, an array-based comparative genomic hybridization.
Welgene Biotech Co.,Ltd. Fundamentals Summary
| 6661 fundamental statistics | |
|---|---|
| Market cap | NT$531.34m |
| Earnings (TTM) | -NT$2.65m |
| Revenue (TTM) | NT$280.55m |
1.9x
P/S Ratio-200.7x
P/E RatioIs 6661 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6661 income statement (TTM) | |
|---|---|
| Revenue | NT$280.55m |
| Cost of Revenue | NT$160.83m |
| Gross Profit | NT$119.72m |
| Other Expenses | NT$122.36m |
| Earnings | -NT$2.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 42.67% |
| Net Profit Margin | -0.94% |
| Debt/Equity Ratio | 42.4% |
How did 6661 perform over the long term?
See historical performance and comparison